Sandoz Sues Amgen Over Alleged Anti-Competitive Practices for Enbrel Biosimilar Market

Sandoz has initiated legal action against Amgen, alleging that the company unlawfully obstructed competition from biosimilars to its widely-used drug, Enbrel. The claims focus on purported strategic acquisitions and illegal extensions of patents that Sandoz argues have been used to deter competitors in the market, ultimately leading to heightened prices in the United States for the treatment of arthritis and other inflammatory conditions. For further details from the original report, you can read more at Law360.